Sign in
4

Changes in Ownership

Alaunos Therapeutics, Inc. Filed Acc 0000899243-23-009000

Options or other derivatives

  • Chief Executive Officer acquired 1,800,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Derivatives
Boyle Kevin S. Sr. Chief Executive Officer 2023-03-15 Grant or award · Employee Stock Option (right to buy) +1,800,000 1,800,000 D
Loading xslF345X03/doc4.xml…